Collaboration, License and Other Strategic Agreements (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended			9 Months Ended
	Apr. 03, 2017	Feb. 28, 2017	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Collaborative Agreements
Net shares issued in connection with license agreement, value						$ 0	$ 12,555
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset				$ 9,300		0	9,300
Endoceutics, Inc.
Collaborative Agreements
Payments related to collaborative arrangement	$ 50,000
Number of shares issued under arrangement (in shares)	600,000
Net shares issued in connection with license agreement, value	$ 13,500
Consideration recorded					$ 83,500
IPR&D expense					5,800
Palatin Technologies, Inc.
Collaborative Agreements
Payments related to collaborative arrangement		$ 60,000
Out-of-pocket expenses (up to)		$ 25,000
Intrarosa | Endoceutics, Inc.
Collaborative Agreements
Out-of-pocket expenses (up to)				20,000			$ 20,000
Intrarosa | Endoceutics, Inc. | Developed technology rights
Collaborative Agreements
Finite-lived intangible assets					$ 77,700
Intrarosa | Endoceutics, Inc. | Delivery Of Intrarosa Launch Quantities
Collaborative Agreements
Payments related to collaborative arrangement				$ 10,000
Intrarosa | Endoceutics, Inc. | First Anniversary Of Closing
Collaborative Agreements
Payments related to collaborative arrangement			$ 10,000
Intrarosa | Endoceutics, Inc. | Tiered Royalties
Collaborative Agreements
Potential milestone payment, triggering event, sales	$ 150,000					$ 150,000
Royalty percentage, maximum	20.00%					20.00%
Net sales threshold, future contingent payments	$ 1,000,000					$ 1,000,000
Period after first commercial sale	10 years					10 years
Intrarosa | Endoceutics, Inc. | First Sales Milestone Achievement
Collaborative Agreements
Potential milestone payment, triggering event, sales	$ 150,000					$ 150,000
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset	15,000					15,000
Intrarosa | Endoceutics, Inc. | Second Sales Milestone Achievement
Collaborative Agreements
Potential milestone payment, triggering event, sales	300,000					300,000
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset	30,000					30,000
Intrarosa | Endoceutics, Inc. | Third Sales Milestone Achievement
Collaborative Agreements
Potential milestone payment, triggering event, sales	500,000					500,000
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset	$ 850,000					$ 850,000
Vyleesi Products | Palatin Technologies, Inc. | Tiered Royalties
Collaborative Agreements
Period after first commercial sale						10 years
Vyleesi Products | Palatin Technologies, Inc. | First Sales Milestone Achievement
Collaborative Agreements
Potential milestone payment, triggering event, sales						$ 250,000
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset						25,000
Vyleesi Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, Acceptance By U.S.Food And Drug Administration Of New Drug Application
Collaborative Agreements
Payments related to collaborative arrangement			$ 20,000
Vyleesi Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, U.S.Food And Drug Administration Approval
Collaborative Agreements
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset						60,000
Vyleesi Products | Palatin Technologies, Inc. | Achievement of Certain Annual Sales Milestones over Course of License Agreement
Collaborative Agreements
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset						$ 300,000